Product name:Saracatinib
CAS:379231-04-6
Molecular Formula:C27H32ClN5O5
Formula Weight:542.03g/mol
Description:It is an oral, highly selective dual inhibitor of the Src and ABL kinases. This monograph highlights the preclinical and clinical studies completed to date for saracatinib, which is currently in phase II clinical development for ovarian, breast, prostate, colorectal, lung, bone, pancreatic, skin, gastric, thymic and head and neck cancers.